Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Week In Review: Abbisko Out-Licenses Rights To Precision NSCLC Medicine For $188 Million

By: TalkMarkets
Abbisko Therapeutics out-licensed Greater China rights to a pre-clinical EGFR-TKI candidate for NSCLC to Allist Pharma in a $188 million deal. Also, Chipscreen Bio acquired greater China rights to a bispecific immunotherapy from Eucure Biopharma.
Related Stocks:
Merck & Co
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback